X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2390) 2390
Publication (118) 118
Government Document (91) 91
Newsletter (24) 24
Book Chapter (14) 14
Book Review (10) 10
Magazine Article (9) 9
Newspaper Article (7) 7
Dissertation (5) 5
Conference Proceeding (2) 2
Reference (2) 2
Streaming Video (2) 2
Book / eBook (1) 1
Journal / eJournal (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1464) 1464
male (1184) 1184
pyridostigmine (943) 943
female (899) 899
adult (679) 679
pyridostigmine bromide - therapeutic use (645) 645
animals (634) 634
pyridostigmine bromide (526) 526
pyridostigmine bromide - pharmacology (507) 507
middle aged (451) 451
index medicus (409) 409
myasthenia gravis - drug therapy (375) 375
rats (347) 347
cholinesterase inhibitors - therapeutic use (328) 328
neurosciences (286) 286
aged (278) 278
pharmacology & pharmacy (268) 268
myasthenia gravis (265) 265
pyridostigmine bromide - administration & dosage (263) 263
endocrinology & metabolism (251) 251
cholinesterase inhibitors - pharmacology (247) 247
adolescent (246) 246
toxicology (240) 240
clinical neurology (230) 230
child (182) 182
myasthenia gravis - diagnosis (177) 177
time factors (168) 168
myasthenia gravis - complications (160) 160
mice (158) 158
dose-response relationship, drug (150) 150
thymectomy (148) 148
growth hormone - blood (137) 137
acetylcholinesterase (132) 132
pyridostigmine bromide - adverse effects (129) 129
treatment outcome (127) 127
soman (125) 125
somatostatin (124) 124
cholinesterase inhibitors (117) 117
myasthenia gravis - therapy (117) 117
cholinesterase inhibitors - administration & dosage (115) 115
rat (115) 115
exposure (113) 113
secretion (109) 109
cholinesterase inhibitors - toxicity (106) 106
acetylcholine (104) 104
growth hormone-releasing hormone - pharmacology (103) 103
kinetics (103) 103
rats, sprague-dawley (100) 100
neostigmine (94) 94
toxicity (93) 93
drug therapy, combination (91) 91
myasthenia gravis - physiopathology (90) 90
analysis (89) 89
brain (89) 89
acetylcholinesterase - metabolism (88) 88
inhibition (88) 88
permethrin (87) 87
drug interactions (86) 86
neurology (86) 86
medicine, general & internal (85) 85
neostigmine - therapeutic use (85) 85
pyridostigmine bromide - toxicity (85) 85
veterans (85) 85
atropine - pharmacology (84) 84
cholinesterase (84) 84
physostigmine (83) 83
growth hormone (82) 82
child, preschool (81) 81
atropine (78) 78
heart rate - drug effects (78) 78
pretreatment (77) 77
research (77) 77
deet (75) 75
growth hormone - metabolism (75) 75
administration, oral (74) 74
neostigmine - pharmacology (74) 74
cholinesterase inhibitors - adverse effects (73) 73
diagnosis (73) 73
nerve agents (73) 73
guinea pigs (72) 72
biochemistry & molecular biology (71) 71
children (71) 71
growth hormone-releasing hormone (71) 71
neuromuscular junction - drug effects (71) 71
electromyography (70) 70
growth hormone - secretion (70) 70
myasthenia gravis - immunology (70) 70
military personnel (69) 69
prednisone - therapeutic use (69) 69
brain - drug effects (68) 68
diagnosis, differential (68) 68
persian gulf war (68) 68
cholinesterases - blood (67) 67
drug synergism (67) 67
carbamates (66) 66
arginine (65) 65
stress (65) 65
acetylcholinesterase - blood (64) 64
anesthesiology (64) 64
pyridostigmine bromide - blood (64) 64
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2266) 2266
German (92) 92
French (38) 38
Spanish (38) 38
Italian (29) 29
Korean (16) 16
Russian (16) 16
Japanese (11) 11
Chinese (8) 8
Portuguese (8) 8
Danish (5) 5
Polish (5) 5
Czech (4) 4
Norwegian (4) 4
Turkish (3) 3
Croatian (2) 2
Dutch (2) 2
Finnish (1) 1
Hebrew (1) 1
Persian (1) 1
Romanian (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Toxicology and Applied Pharmacology, ISSN 0041-008X, 06/2014, Volume 277, Issue 3, p. 298
Many veterans of the 1991 Gulf War (GW) returned from that conflict with a widespread chronic pain affecting deep tissues. Recently, we have shown that a 60day... 
Insecticides | Pyridostigmine
Journal Article
Neurotoxicology, ISSN 0161-813X, 12/2013, Volume 39, p. 72
acents Rats were treated for 60 days with permethrin, chlorpyrifos and pyridostigmine bromide. acents Eight weeks after treatment ceased, there were no... 
Insecticides | Pyridostigmine
Journal Article
Neurochemical Research, ISSN 0364-3190, 7/2017, Volume 42, Issue 7, pp. 1962 - 1971
Galantamine hydrobromide and (−)huperzine A, centrally active reversible acetylcholinesterase inhibitors, are potentially superior to the current standard,... 
Neurochemistry | Biochemistry, general | Neurology | Neurosciences | Biomedicine | Galantamine | Pyridostigmine bromide | Behavioral toxicity | Acetylcholinesterase | Nerve agent | Huperzine | Cell Biology | NICOTINIC RECEPTORS | ALZHEIMERS-DISEASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | SOMAN | NEUROSCIENCES | HUPERZINE-A | INDUCED SEIZURES | TREATMENT STRATEGY | PRETREATMENT | IN-VIVO | ALLOSTERIC POTENTIATION | Cholinesterase Inhibitors - pharmacokinetics | Seizures - prevention & control | Alkaloids - pharmacokinetics | Sesquiterpenes - pharmacokinetics | Macaca fascicularis | Male | Seizures - metabolism | Pyridostigmine Bromide - pharmacokinetics | Sesquiterpenes - adverse effects | Sesquiterpenes - therapeutic use | Seizures - chemically induced | Soman - toxicity | Time Factors | Reaction Time - drug effects | Pyridostigmine Bromide - adverse effects | Pyridostigmine Bromide - therapeutic use | Alkaloids - adverse effects | Treatment Outcome | Reaction Time - physiology | Animals | Convulsants - toxicity | Cholinesterase Inhibitors - adverse effects | Alkaloids - therapeutic use | Chemical Warfare Agents - toxicity | Cholinesterase Inhibitors - therapeutic use | Nerve gas | Pyridostigmine | War use | Galanthamine | Gases, Asphyxiating and poisonous | Operant conditioning | Toxicity | Central nervous system | Recovery of function | Chemical warfare | Monkeys | Huperzine A | Recovery | Lethal dose | Inhibitors | Intoxication | Safety | Inhibition | Pretreatment | Soman | Convulsions | Drug dosages
Journal Article
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 304 - 10
Journal Article
The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis, 10/2003
CONTEXT: Patients with myasthenia gravis receive pyridostigmine, an anticholinesterase agent, as a part of therapy. These patients demonstrate a heightened... 
Medicine | Vecuronium, Myasthenia gravis, Pyridostigmine, Non-depolarising block jp03087
Journal
Gut, ISSN 0017-5749, 05/2013, Volume 62, Issue 5, pp. 708 - 715
Objectives Chronic constipation in diabetes mellitus is associated with colonic motor dysfunction and is managed with laxatives. Cholinesterase inhibitors... 
NEUROGENIC ORTHOSTATIC HYPOTENSION | MOTOR | PYRIDOSTIGMINE | PERFORMANCE-CHARACTERISTICS | DISORDERS | SYMPTOMS | ACETYLCHOLINESTERASE INHIBITORS | TRANSIT-TIME | GASTROENTEROLOGY & HEPATOLOGY | IRRITABLE-BOWEL-SYNDROME | AUTONOMIC NEUROPATHY | Humans | Middle Aged | Gastrointestinal Motility - drug effects | Male | Diabetes Mellitus, Type 1 - complications | Dose-Response Relationship, Drug | Pyridostigmine Bromide - administration & dosage | Adult | Female | Constipation - drug therapy | Diabetes Mellitus, Type 2 - complications | Pyridostigmine Bromide - adverse effects | Pyridostigmine Bromide - therapeutic use | Double-Blind Method | Administration, Oral | Defecation - drug effects | Diabetes Mellitus - drug therapy | Treatment Outcome | Gastrointestinal Transit - drug effects | Constipation - etiology | Diabetes Mellitus, Type 1 - drug therapy | Algorithms | Cholinesterase Inhibitors - administration & dosage | Adolescent | Cholinesterase Inhibitors - adverse effects | Aged | Cholinesterase Inhibitors - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Care and treatment | Motility | Demographic aspects | Gastrointestinal system | Dosage and administration | Research | Diabetes | Cholinesterase inhibitors | Constipation | Studies | Rodents | Pharmacy | Clinical trials | Laxatives | Colon | Drug dosages
Journal Article
Journal of Clinical Anesthesia, ISSN 0952-8180, 11/2019, Volume 57, pp. 63 - 63
Journal Article
Archives of Pharmacal Research, ISSN 0253-6269, 3/2012, Volume 35, Issue 3, pp. 499 - 508
Journal Article
Drug Development and Industrial Pharmacy, ISSN 0363-9045, 9/2013, Volume 39, Issue 9, pp. 1364 - 1371
Journal Article
Revue Neurologique, ISSN 0035-3787, 03/2017, Volume 173, pp. S152 - S152
La survenue d’une dystonie au cours de la myasthénie (MG) a été rarement rapportée, en tant qu’association, ou effet secondaire de la Pyridostigmine. La... 
Myasthénie | Pyridostigmine | Dystonie
Journal Article
Scientific Reports, ISSN 2045-2322, 11/2015, Volume 5, Issue 1, p. 17108
Journal Article
American Journal of Physiology - Regulatory Integrative and Comparative Physiology, ISSN 0363-6119, 10/2013, Volume 305, Issue 8, pp. R908 - R916
Journal Article